Zum Hauptinhalt springen

Hashimoto-Thyreoiditis

Medizinische Fachkräfte

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our Gesundheitsartikel more useful.

Lesen Sie unten weiter

What is Hashimoto’s thyroiditis?

Hashimoto's thyroiditis is named after Dr Hakaru Hashimoto, who first described the condition in 1912.1

It is part of the spectrum of autoimmune disease and the most common cause of goitrous hypothyroidism in non-iodine-deficient areas. However, there is also an atrophic form of autoimmune thyroiditis (Ord's thyroiditis) which is more common in Europe.

In this condition, typically there is aggressive destruction of thyroid cells by various cell- and antibody-mediated immune processes (in contrast to the stimulatory effect seen in Graves' disease). It is not yet understood why this occurs.

The major environmental triggers of autoimmune thyroid disease include iodine, medications, infection, smoking and diet. Patients' iron levels (particularly in menstruating women), vitamin D status and selenium intake (in areas of iodine deficiency/excess) are important.2

  • Antibodies binding to and blocking the thyroid-stimulating hormone (TSH) receptor have been described and may contribute to further impairment in thyroid function.

  • The result is inadequate thyroid hormone production and secretion, although initially both preformed thyroxine (T4) and triiodothyronine (T3) may 'leak' into the circulation from damaged cells.

  • The goitrous form (rather than atrophic) is associated with HLA-DR5.

  • Twin studies indicate that there is about 70% genetic contribution to autoimmune thyroid disease.3

Lesen Sie unten weiter

  • In white people it is estimated at approximately 5%. The dysfunction of the gland may be clinically evident (0.1-2% of the population) or subclinical (10-15%). The incidence increases with the age (the peak of the number of cases is between 45 and 65); however, it can also be diagnosed in children.4

  • The disease is often quoted as at least 10 times greater but a more recent meta-analysis finds it is 4 times as frequent in women as in men.5

  • It occurs especially during the decades from ages 30 to 50, but may be seen in any age group, including children.6

  • In children, the most common age at presentation is adolescence but the disease may occur at any time, rarely even in children under 1 year of age.7

  • The thyroid gland may enlarge rapidly:

    • Occasionally it is associated with dyspnoea or dysphagia from pressure on structures in the neck, or with mild pain and tenderness.8

    • Rarely, pain is persistent and unresponsive to analgesics and requires medical therapy or surgery.

    • The goitre of Hashimoto's thyroiditis may remain unchanged for decades but usually it gradually increases in size.

    • Occasionally the course is marked by symptoms of mild thyrotoxicosis, especially during the early phase of the disease.

  • Symptoms and signs of Hypothyreose may be present when first seen, or commonly develop over a period of several years. These may include:6

    • Fatigue, Verstopfung, dry skin and weight gain.

    • Kälteintoleranz.

    • Slowed movement and loss of energy.

    • Decreased sweating.

    • Mild nerve deafness.

    • Periphere Neuropathie.

    • Menstrual irregularities (typically Menorrhagie).

    • Depression, Demenz and memory loss.

    • Hair loss from an autoimmune process.

  • Eventually, thyroid atrophy and myxoedema may occur.

Lesen Sie unten weiter

Hashimoto's thyroiditis is based on clinical findings in combination with histological appearance. The thyroid gland shows diffuse lymphocytic and plasma cell infiltration with formation of lymphoid follicles from follicular hyperplasia and damage to the follicular basement membrane.6 Atrophy of the thyroid parenchyma is usually evident. Thyroid autoantibodies may also be seen.

  • TSH levels; this is a sensitive test of thyroid function. Levels are usually raised in hypothyroidism due to Hashimoto's thyroiditis (but also in primary hypothyroidism of any cause).

  • Thyroid autoantibodies - anti-thyroid peroxidase (anti-TPO) and also anti-thyroglobulin (anti-Tg) antibodies.

  • Thyroid ultrasound - usually not necessary in diagnosing Hashimoto's thyroiditis but it is useful in assessing thyroid size, echotexture and, most importantly, the presence of thyroid nodules.

  • Radioactive iodine uptake and scan are used to classify a nodule as hot or cold. A cold thyroid nodule would indicate a higher risk for malignancy and would need a fine-needle aspiration biopsy.

Other studies are only performed to evaluate complications of primary hypothyroidism when indicated - eg, dyslipidaemia.

Hashimoto's thyroiditis and hypothyroidism are associated with other autoimmune conditions:

See also the separate articles on Hypothyreose und Schilddrüsenerkrankung in der Schwangerschaft.

Pharmakologisch

  • Thyroid hormone replacement - orally administered levothyroxine sodium, usually for life.

  • The dose should be titrated to the individual patient's needs. The aim is to restore a clinically and biochemically euthyroid state.9

  • Patients who are older than 50 years (and younger patients with cardiac disease) should be started on a low dose of 25 micrograms (0.025 mg) per day. Their clinical and biochemical state is then re-examined after 6-8 weeks.

Chirurgisch

Indications for surgery include:

  • A large goitre with obstructive symptoms - eg, Dysphagie oder stridor.

  • Presence of a malignant nodule.

  • Presence of a lymphoma diagnosed on fine-needle aspiration.

  • Cosmetic reasons for unsightly, large goitres.

  • Over-replacement with thyroxine, causing accelerated bone loss or increased heart rate.

  • Hyperlipidämie and consequences, if untreated.

  • Hashimoto's encephalopathy.10

  • Myxödemkoma (due to extreme hypothyroidism). Untreated, this has a poor prognosis and a high mortality rate (around 30%).11

  • Chronic inflammation, leading to neoplastic transformation, is a well-established clinical phenomenon. Hashimoto's thyroiditis carries a significantly increased risk of papillary thyroid cancer.12

With early diagnosis and levothyroxine replacement therapy, the prognosis is excellent and patients may achieve normal thyroid levels. However, normal levels do not always equate with normal functioning.

Exclusive updates for healthcare professionals

Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.

Bitte geben Sie eine gültige E-Mail-Adresse ein

By subscribing you accept our Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

Weiterführende Literatur und Referenzen

  1. Hiromatsu Y, Satoh H, Amino N; Hashimoto's thyroiditis: history and future outlook. Hormones (Athens). 2013 Jan-Mar;12(1):12-8.
  2. Hu S, Rayman MP; Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis. Thyroid. 2017 May;27(5):597-610. doi: 10.1089/thy.2016.0635. Epub 2017 Apr 6.
  3. Effraimidis G, Wiersinga WM; Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014 Jun;170(6):R241-52. doi: 10.1530/EJE-14-0047. Epub 2014 Mar 7.
  4. Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al; Immune disorders in Hashimoto's thyroiditis: what do we know so far? J Immunol Res. 2015;2015:979167. doi: 10.1155/2015/979167. Epub 2015 Apr 27.
  5. Hu X, Chen Y, Shen Y, et al; Global prevalence and epidemiological trends of Hashimoto's thyroiditis in adults: A systematic review and meta-analysis. Front Public Health. 2022 Oct 13;10:1020709. doi: 10.3389/fpubh.2022.1020709. eCollection 2022.
  6. Mincer DL, Jialal I; Hashimoto Thyroiditis.
  7. Brown RS; Autoimmune thyroiditis in childhood. J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1:45-9. doi: 10.4274/jcrpe.855. Epub 2012 Nov 15.
  8. Yuan J, Qi S, Zhang X, et al; Local symptoms of Hashimoto's thyroiditis: A systematic review. Front Endocrinol (Lausanne). 2023 Jan 19;13:1076793. doi: 10.3389/fendo.2022.1076793. eCollection 2022.
  9. Hypothyreose; NICE CKS, Mai 2021 (nur in Großbritannien zugänglich)
  10. Ogbebor O, Patel K; Hashimoto's encephalopathy: a rare cause of delirium. BMJ Case Rep. 2019 Sep 6;12(9). pii: 12/9/e230118. doi: 10.1136/bcr-2019-230118.
  11. Ylli D, Klubo-Gwiezdzinska J, Wartofsky L; Thyroid emergencies. Pol Arch Intern Med. 2019 Aug 29;129(7-8):526-534. doi: 10.20452/pamw.14876. Epub 2019 Jun 25.
  12. Uhliarova B, Hajtman A; Hashimoto's thyroiditis - an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol. 2018 Nov - Dec;84(6):729-735. doi: 10.1016/j.bjorl.2017.08.012. Epub 2017 Sep 14.

Lesen Sie unten weiter

About the authorView full bio

Author image

Dr Hayley Willacy, FRCGP

Allgemeinmediziner, Medizinischer Autor

MBChB (1992), DRCOG, DFFP, MRCOG (Part 1) MRCGP (2007), DFSRH (2013), MSc - medical education (2020)

Dr Hayley Willacy was an NHS GP working in northwest England, who retired from clinical practice in 2022 after 30 years. 

About the reviewerView full bio

Author image

Dr Colin Tidy, MRCGP

Allgemeinmediziner, Medizinischer Autor

MBBS, MRCGP, MRCP (Paediatrics), DCH

Dr. Colin Tidy ist ein NHS-Arzt mit Sitz in Oxfordshire.

Artikelverlauf

Die Informationen auf dieser Seite wurden von qualifizierten Klinikern verfasst und begutachtet.

flu eligibility checker

Fragen, teilen, verbinden.

Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.

Symptom-Checker für Patienten

Fühlen Sie sich unwohl?

Bewerten Sie Ihre Symptome online kostenlos